摘要
慢性乙型肝炎病毒(hepatitis B virus,HBV)感染是世界范围内的重大健康问题。抗HBV的治疗以核苷(酸)类似物[nucleos(t)ides,NUCs]为主,是其关键干预措施。抗HBV药物治疗可延缓肝硬化(liver cirrhosis,LC)病情进展、减少失代偿、减少肝细胞癌(hepatocellular carcinoma,HCC)发生,甚至可以使部分LC失代偿期患者“再代偿”。当对比不同抗病毒药物之间作用强弱时,目前研究尚无定论。文章综述了抗病毒治疗HBV-LC患者的临床研究结果,以比较不同的NUCs对HBV-LC患者病毒标志物相关指标及临床结局影响作用的强弱,以促进临床实践的进一步优化。
Chronic hepatitis B virus(HBV)infection is a major health problem worldwide.Anti-HBV treatment,predominantly nucleos(t)ides(NUCs),is the key intervention.Anti-HBV therapy can delay the progression of liver cirrhosis(LC),reduce decompensation,reduce the risk of hepatocellular carcinoma(HCC),and even"recompensate"some patients with decompensated LC.When comparing the effects of different antiviral drugs,the current research is inconclusive.This paper summarizes the clinical researches regarding antiviral treatment for HBV-LC patients to compare the effects of different NUCs on HBV marker-related indicators and clinical outcomes of HBV-LC patients,in order to promote the further optimization of clinical practice.
作者
王哲
胡可
于岩岩
徐小元
徐京杭
WANG Zhe;HU Ke;YU Yan-yan;XU Xiao-yuan;XU Jing-hang(Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China)
出处
《中国实用内科杂志》
CSCD
北大核心
2023年第5期360-363,共4页
Chinese Journal of Practical Internal Medicine
基金
国家十三五科技重大专项(2017ZX10202202)。
关键词
乙型肝炎
肝硬化
抗病毒药物
核苷酸类似物
核苷类似物
结局
hepatitis B
liver cirrhosis
antiviral drugs
nucleotide analogues
nucleoside analogues
outcome
